Up to date list of publications on Pubmed
55. The structural basis of agonist-induced activation in constitutively active rhodopsin. Standfuss J, Edwards PC, D'Antona A, Fransen M, Xie G, Oprian DD, Schertler GF. Nature (2011) 471 (7340), pp. 656-60.
54. Crystal structure of a thermally stable rhodopsin mutant. Standfuss J, Xie G, Edwards PC, Burghammer M, Oprian DD, Schertler GF. J. Mol. Biol. (2007) 372 (5), pp. 1179-88.
53. Transducin activation by nanoscale lipid bilayers containing one and two rhodopsins. Bayburt TH, Leitz AJ, Xie G, Oprian DD, Sligar SG. J. Biol. Chem. (2007) 282 (20), pp. 14875-81.
52. Recoverin binds exclusively to an amphipathic peptide at the N terminus of rhodopsin kinase, inhibiting rhodopsin phosphorylation without affecting catalytic activity of the kinase. Higgins MK, Oprian DD, Schertler GF. J. Biol. Chem. (2006) 281 (28), pp. 19426-32.
51. Mislocalized rhodopsin does not require activation to cause retinal degeneration and neurite outgrowth in Xenopus laevis. Tam BM, Xie G, Oprian DD, Moritz OL. J. Neurosci. (2006) 26 (1), pp. 203-9.
50. A dark and constitutively active mutant of the tiger salamander UV pigment. Kono M, Crouch RK, Oprian DD. Biochemistry (2005) 44 (2), p. 799-804.
49. Structural origins of constitutive activation in rhodopsin: Role of the K296/E113 salt bridge. Kim JM, Altenbach C, Kono M, Oprian DD, Hubbell WL, Khorana HG. Proc. Natl. Acad. Sci. USA (2004) 101 (34), pp. 12508-13.
48. Role of the 9-methyl group of retinal in cone visual pigments. Das J, Crouch RK, Ma JX, Oprian DD, Kono M. Biochemistry (2004) 43 (18), pp. 5532-8.
47. Opsin activation as a cause of congenital night blindness. Jin S, Cornwall MC, Oprian DD. Nat. Neurosci. (2003) 6 (7), pp. 731-5.
46. An improved rhodopsin/EGFP fusion protein for use in the generation of transgenic Xenopus laevis. Jin S, McKee TD, Oprian DD. FEBS Lett. (2003) 542 (1-3), pp. 142-6.
45. Phototaxis, chemotaxis and the missing link. Oprian DD. Trends Biochem. Sci. (2003) 28 (4), pp. 167-9.
44. Characterization of rhodopsin congenital night blindness mutant T94I. Gross AK, Rao VR, Oprian DD. Biochemistry (2003) 42 (7), pp. 2009-15.
43. Slow binding of retinal to rhodopsin mutants G90D and T94D. Gross AK, Xie G, Oprian DD. Biochemistry (2003) 42 (7), pp. 2002-8.
42. An opsin mutant with increased thermal stability. Xie G, Gross AK, Oprian DD. Biochemistry (2003) 42 (7), pp. 1995-2001.
41. Spectral tuning in the mammalian short-wavelength sensitive cone pigments. Fasick JI, Applebury ML, Oprian DD. Biochemistry (2002) 41 (21), pp. 6860-5.
40. Grafting segments from the extracellular surface of CCR5 onto a bacteriorhodopsin transmembrane scaffold confers HIV-1 coreceptor activity. Abdulaev NG, Strassmaier TT, Ngo T, Chen R, Luecke H, Oprian DD, Ridge KD. Structure (2002) 10 (4), pp. 515-25.
39. A visual pigment expressed in both rod and cone photoreceptors. Ma J, Znoiko S, Othersen KL, Ryan JC, Das J, Isayama T, Kono M, Oprian DD, Corson DW, Cornwall MC, Cameron DA, Harosi FI, Makino CL, Crouch RK. Neuron (2001) 32 (3), pp. 451-61.
38. Salamander UV cone pigment: sequence, expression, and spectral properties. Ma JX, Kono M, Xu L, Das J, Ryan JC, Hazard ES 3rd, Oprian DD, Crouch RK. Vis. Neurosci (2001) 18 (3), pp. 393-9.
37. G protein-coupled receptor activation: analysis of a highly constrained, "straitjacketed" rhodopsin. Struthers M, Yu H, Oprian DD. Biochemistry (2000) 39 (27), pp. 7938-42.
36. Mapping tertiary contacts between amino acid residues within rhodopsin. Struthers M, Oprian DD. Methods Enzymol. (2000) 315, pp. 130-43.
35. Spectral tuning in the human blue cone pigment. Fasick JI, Lee N, Oprian DD. Biochemistry (1999) 38 (36), pp. 1593-6.
34. Tertiary interactions between transmembrane segments 3 and 5 near the cytoplasmic side of rhodopsin. Yu H, Oprian DD. Biochemistry (1999) 38 (37), pp. 12033-40.
33. State-dependent disulfide cross-linking in rhodopsin. Yu H, Kono M, Oprian DD. Biochemistry (1999) 38 (37), pp. 12028-32.
32. Tertiary interactions between the fifth and sixth transmembrane segments of rhodopsin. Struthers M, Yu H, Kono M, Oprian DD. Biochemistry (1999) 38 (20), pp. 6597-603.
31. Disulfide bond exchange in rhodopsin. Kono M, Yu H, Oprian DD. Biochemistry (1998) 37 (5), pp. 1302-5.
30. Synthesis and characterization of a novel retinylamine analog inhibitor of constitutively active rhodopsin mutants found in patients with autosomal dominant retinitis pigmentosa. Yang T, Snider BB, Oprian DD. Proc. Natl. Acad. Sci. USA (1997) 94 (25), pp. 13559-64.
29. In vitro assay for trans-phosphorylation of rhodopsin by rhodopsin kinase. Rim J, Faurobert E, Hurley JB, Oprian DD. Biochemistry (1997) 36 (23), pp. 7064-70.
28. Resonance Raman examination of the wavelength regulation mechanism in human visual pigments. Kochendoerfer GG, Wang Z, Oprian DD, Mathies RA. Biochemistry (1997) 36 (22) pp. 6577-87.
27. Activating mutations of rhodopsin and other G protein-coupled receptors. Rao VR, Oprian DD. Annu. Rev. Biophys. Biomol. Struct. (1996) 25, pp. 287-314.
26. A general method for mapping tertiary contacts between amino acid residues in membrane-embedded proteins. Yu H, Kono M, McKee TD, Oprian DD. Biochemistry (1995) 34 (46), pp. 14963-9.
25. Constitutive activation of opsin: interaction of mutants with rhodopsin kinase and arrestin. Rim J, Oprian DD. Biochemistry (1995) 34 (37), pp. 11938-45.
24. Molecular determinants of human red/green color discrimination. Asenjo AB, Rim J, Oprian DD. Neuron (1994) 12 (5), pp.1131-8.
23. Active site-directed inactivation of constitutively active mutants of rhodopsin. Govardhan CP, Oprian DD. J. Biol. Chem. (1994) 269 (9), pp. 6524-7.
22. Rhodopsin mutation G90D and a molecular mechanism for congenital night blindness. Rao VR, Cohen GB, Oprian DD. Nature (1994 367 (6464), pp. 639-42.
21. Heterozygous missense mutation in the rhodopsin gene as a cause of congenital stationary night blindness. Dryja TP, Berson EL, Rao VR, Oprian DD. Nat. Genet. (1993) 4 (3), pp. 280-3.
20. Constitutive activation of opsin: influence of charge at position 134 and size at position 296. Cohen GB, Yang T, Robinson PR, Oprian DD. Biochemistry (1993) 32 (23), pp. 6111-5.
19. Identification of the Cl(-)-binding site in the human red and green color vision pigments. Wang Z, Asenjo AB, Oprian DD. Biochemistry (1993) 32 (9), pp. 2125-30.
18. Mechanism of activation and inactivation of opsin: role of Glu113 and Lys296. Cohen GB, Oprian DD, Robinson PR. Biochemistry (1992) 31 (50), pp. 12592-601.
17. Changing the location of the Schiff base counterion in rhodopsin. Zhukovsky EA, Robinson PR, Oprian DD. Biochemistry (1992 31 (42), pp. 10400-5.
16. Constitutively active mutants of rhodopsin. Robinson PR, Cohen GB, Zhukovsky EA, Oprian DD. Neuron (1992) 9 (4), pp. 719-25
15. Molecular determinants of spectral properties and signal transduction in the visual pigments. Oprian DD. Curr. Opin. Neurobiol. (1992) 2 (4), pp. 428-32.
14. The ligand-binding domain of rhodopsin and other G protein-linked receptors. Oprian DD. J. Bioenerg. Biomembr. (1992) 24 (2), p. 211-7.
13. Design, chemical synthesis, and expression of genes for the three human color vision pigments. Oprian DD, Asenjo AB, Lee N, Pelletier SL. Biochemistry (1991) 30 (48), pp. 11367-72.
12. Transducin activation by rhodopsin without a covalent bond to the 11-cis-retinal chromophore. Zhukovsky EA, Robinson PR, Oprian DD. Science (1991) 251 (4993), pp. 558-60.
11. Effect of carboxylic acid side chains on the absorption maximum of visual pigments. Zhukovsky EA, Oprian DD. Science (1989) 246 (4932), pp. 928-30.
10. A single amino acid substitution in rhodopsin (lysine-248->leucine) prevents activation of transducin. Franke RR, Sakmar TP, Oprian DD, Khorana HG. J. Biol. Chem. (1988) 263 (5), pp. 2119-22
9. Expression of a synthetic bovine rhodopsin gene in monkey kidney cells. Oprian DD, Molday RS, Kaufman RJ, Khorana HG. Proc. Natl. Acad. Sci. USA (1987) 84 (24), pp. 8874-8.
8. Total synthesis of a gene for bovine rhodopsin. Ferretti L, Karnik SS, Khorana HG, Nassal M, Oprian DD. Proc. Natl. Acad. Sci. USA (1986), 83 (3), pp. 599-603.
7. cDNA clones encoding bovine interphotoreceptor retinoid binding protein. Barrett DJ, Redmond TM, Wiggert B,Oprian DD, Chader GJ, Nickerson JM. Biochem. Biophys. Res. Commun. (1985) 131 (3), pp. 1086-93.
6. cDNA-derived amino acid sequence of the gamma subunit of GTPase from bovine rod outer segments. Yatsunami K, Pandya BV, Oprian DD, Khorana HG. Proc. Natl. Acad. Sci. USA (1985) 82 (7), pp. 1936-40.
5. Properties of the oxygenated form of liver microsomal cytochrome P-450. Oprian DD, Gorsky LD, Coon MJ. J. Biol. Chem. (1983) 258 (14), pp. 8684-91.
4. Oxidation-reduction states of FMN and FAD in NADPH-cytochrome P-450 reductase during reduction by NADPH. Oprian DD, Coon MJ. J. Biol. Chem. (1982) 257 (15), pp. 8935-44.
3. Kinetics of reduction of cytochrome P-450LM4 in a reconstituted liver microsomal enzyme system. Oprian DD, Vatsis KP, Coon MJ. J. Biol. Chem. (1979) 254 (18), pp. 8895-902.
2. Kinetics of reduction of purified liver microsomal cytochrome P-450 in the reconstituted enzyme system studied by stopped flow spectrophotometry. Vatsis KP, Oprian DD, Coon MJ. Acta Biol. Med. Ger. (1979) 38 (2-3), pp. 459-73.
1. Mechanistic studies with purified components of the liver microsomal hydroxylation system: Spectral intermediates in reaction of cytochrome P-450 with peroxy compounds. Coon MJ, Blake RC 2nd, Oprian DD, Ballou DP. Acta Biol. Med. Ger. (1979) 38 (2-3), pp. 449-58.
  Up to date list of publications on Pubmed